• Specific binding of spheres to thrombi under flow condition

    read more
  • Specific binding of live cells to thrombi under flow condition

    read more
  • Targeted delivery of particles to mouse mesenteric arterial thrombosis

    read more
  • Ta group in 2019

  • Ta group in 2019

  • Ta Group in 2020

  • Ta Group in 2020

Smart magnetic resonance imaging nano-sensor for detecting and grading diseases

The early detection and accurate characterization of life-threatening diseases such as cardiovascular disease and cancer are critical to the design of treatment.

read more

Nano-theranostics of life-threatening diseases

This research theme focuses on the development of novel nanomaterials for the diagnosis and treatment of life-threatening diseases such as cancers, thrombosis, cardiovascular and inflammatory diseases.

read more

Cell delivery and imaging

This theme develops novel strategies for cell homing and tracking in vivo using modern imaging techniques such as magnetic resonance imaging and photoacoustic imaging

read more

Innovative reversible blood clotting agents for emergency treatment of internal bleeding

Currently, there is a lack of effective therapeutics for internal bleeding following a traumatic event. In this project, novel reversible blood clotting nanomaterials will be designed to be able to hunt for internal injuries and bleeding and then stop the bleeding quickly.

read more

Cardiovascular diseases on the chip

Every newly developed drug need to be tested through several rounds of animal testing before they can be tested on human. However, a rodent or chimp’s response to a medication does not alsway translate so smoothly in a person.

read more

About Hang Ta Group

The research in Associate Professor Hang T. Ta’s Laboratory (NanoMicro Lab) focuses on the development of advanced nanomaterials for molecular imaging, diagnosis, treatment and also theranostics of life-threatening diseases such as cardiovascular diseases, inflammatory diseases, cancers and bleeding disorders. The group is also dedicated to the development of cardiovascular disease on microfluidic devices for fundamental investigation of the disease, drug testing and screening, and also for diagnostics of the disease.

read more
52
REFEREED PUBLICATIONS
3.9 million AUD
FUNDING
10
RESEARCH MEMBERS